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Climbing their way through their maternity.
At steeper gradients they rest awhile
And ponder every step their Herculean task.
Prepare for last assault, and summit reached
They sit and stare, at all the beauty lying there
And wrap the sun, the moon, the stars
Round the small bundle in their arms.

Christine Bress

ABSTRACT

In a retrospective study, a group of 77 pregnant women who had
positive diabetic screening tests and negative oral glucose tolerance
tests (OGTTs) was compared with a group of 251 pregnant women who had
negative screening tests.

Statistically significant differences were

evident with respect to age >_ 35 years, obesity, history of stillbirth(s),
neonatal respiratory difficulties, and birth weight >. 4000 grams; however,
when the birth weights were corrected for gestational age, sex, mother's
height, mother's weight, and parity, no macrosomia was evident.

No

significant differences were noted with respect to 32 other variables.
The probability of occurrence of significant differences due to
chance alone is discussed.

While the results of this study do not disprove

the hypothesis that women with positive screening tests and negative
OGTTs are at an early stage of prediabetes, they reassure the practitioner
that such women do not have significantly increased morbidity of pregnancy.
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INTRODUCTION

Gestational diabetes is a disorder of carbohydrate metabolism
limited to pregnancy.

Women with the disorder demonstrate normal glucose

metabolism prior to and subsequent to the pregnancy.
Gestational diabetes is recognized as an important factor in
increasing perinatal morbidity and mortality rates.

Therefore,

obstetricians have advocated a variety of criteria-test combinations
to help identify gestational diabetics.

In many obstetrical practices

and clinics women fulfilling certain criteria are screened for abnormal
glucose metabolism.

The screening test usually yields a fasting blood

glucose level and a post-prandial level.

If the latter is above

a certain limit, the screening test is considered positive, and a
full 3 hour glucose tolerance test (GTT) is performed to further assess
the woman's carbohydrate metabolism.

If the GTT results are abnormal,

the woman is considered a gestational diabetic and is managed accordingly.
On the other hand, if the GTT results are within normal limits, the
screen is thought of as falsely positive, and she is managed as a normal
gravida.

No studies have proved that this group of women does not

differ from women who have negative screening test results, in terms
of complications and outcome of pregnancy.

It is the objective of

this study to compare two such groups of women with respect to a
variety of prenatal, perinatal, and neonatal variables.

2
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BACKGROUND

Gestational diabetes was first recognized as an entity in the
1920'sJ

However, it was not until decades later that physicians re¬

alized its association with increased rates of fetal and maternal morbidity
2
and mortality. In a retrospective study published in 1946, Miller
noted that in the years preceding the development of overt diabetes,
women had an increased risk of delivering a macrosomic baby (^ 4500gm),
and/or losing the infant in a perinatal death.

These women were considered

prediabetics with borderline (but normal) carbohydrate metabolism, a state
that might change to overt diabetes with increased diabetogenic stress
and/or time.
Over the last two decades, pregnancy has been recognized as a
3
diabetogenic factor, and the pathophysiology of gestational diabetes
4
has been elucidated.
During pregnancy, two major factors cause an
alteration in the distribution of energy substrates.

The first is the

fetus being the passive recipient of glucose (transported across the
placenta by facilitated diffusion), and of actively transported amino
acids.

The second is the placental secretion of contrainsulin factors

that render the body tissues somewhat "resistant" to insulin.

The normal

pancreas compensates for this decreased effectiveness of insulin by
increasing its secretion.

In the gestational diabetic, the functional

reserve of the islet cell may be inadequate to fulfill the increased
demand, and hyperglycemia becomes evident.
A widely accepted hypothesis that links maternal hyperglycemia
with the increased morbidity and mortality of infants of diabetic

-

■
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mothers is the hyperglycemia-hyperinsulinemia hypothesis.

5

It suggests

that many of the complications are caused by fetal hyperinsulinemia.

It

is thought that maternal hyperglycemia results in fetal hyperglycemia, and
this in turn, induces hypertrophy and hyperplasia of the fetal islet cells
and fetal hyperinsulinemia.

The excess fetal insulin acts as a growth

hormone, causing increased fat and glycogen deposition, as well as visceromegaly.

J

Oakley et al

in a study published in 1972, suggested that fetal hyperinsuli-

nemia and possible subsequent hypoglycemia (e.g. in a fasting state) might
contribute to the increased perinatal mortality rates associated with
diabetes.

Fetal hyperinsulinemia has also been implicated in causing
O

neonatal hypoglycemia.

After birth, the infant is no longer exposed to

the high levels of glucose present in the diabetic mother's blood.

The

neonate's hyperinsulinemia causes rapid decline in the blood glucose level.

g

Glycogen stores are not mobilized rapidly due to attenuated catecholamine
secretion in such neonates.^

The combination of the two factors causes

hypoglycemia in the infant of the diabetic mother.
A report published by Smith et al (1975)^ helped support the notion
that fetal hyperinsulinemia may be a factor in increasing the incidence
of another complication, the respiratory distress syndrome, among infants
of diabetic mothers.

12

Insulin was reported to interfere with the synthesis

of lecithin by cultured fetal lung cells.^
If the hyperglycemia-hyperinsulinemia theory is valid, then the
morbidity rates associated with diabetic pregnancies should be reducable
with tight metabolic control of the pregnant diabetic.
supported by a number of studies.

1 ^-1 fi

This has been
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Screening for Gestational Diabetes:
Since the recognition of the association of gestational diabetes
with increased rates of maternal and fetal morbidity and mortality,
the importance of identifying gestational diabetics has been undisputed.
To detect all cases of gestational diabetes, all pregnant women would
have to undergo a GTT.

However, since only a small percentage of the

tests would yield positive results, cost-effectiveness (financial and
otherwise) would render such an endeavor unjustified.

Therefore,

criteria were needed for the selection of those women who should undergo
a GTT.
Many criteria-test combinations for the detection and diagnosis
of gestational diabetes have been advocated.

The criteria used for

"diabetic testing" have been those of positive history of glycosuria,
obesity, spontaneous abortions, polyhydramnios,

stillbirth, toxemia,

excessive weight gain in pregnancy, recurrent prematurity, large for
gestational age offspring, a newborn with congenital anomaly, and/or
family history of diabetes.

17-22

It has been suggested that any

woman fulfilling any of these criteria should undergo a GTT during
each trimester of pregnancy.

It has

been thought that the greater

the number of criteria that a woman fulfilled, the higher her chances
of developing gestational diabetes were.

23

Among the variety of tests used to screen for or diagnose
gestational diabetes have been 1 hour post-prandial blood glucose
25-26
2 hour post-prandial blood glucose measurements,
27
?q
intravenus GTT,
and oral GTT (OGTT).
Also, different glucose

measurements,

24

loads (e.g. 50gm, 75gm, etc.) have been used.

In 1973 O'Sullivan et al

24

suggested the use of a one hour screening test for the selection of
those women that should undergo a three hour GTT.

Their proposal was

based on the study of 752 pregnant women, all of whom underwent a 1 hour
screening test and a 3 hour OGTT.

In the screening test described, the

subject ingested 50 grams of glucose, and 1 hour later a venous whole
blood glucose was obtained.

A threshold value of 130 mg/dl was decided

upon, and if this, threshold was reached or exceeded, a glucose tolerance
test was suggested.

When comparing the efficacy of using the 1 hour

screening test as compared to historical data as criteria for GTT ad¬
ministration, it was noted that a greater percentage of gestational
diabetics (78.9% vs. 63%) were identified by the screening tests while
fewer GTT's would be necessary (14.5% vs. 44.5%).
Criteria for OGTT:
Because of the physiological changes during pregnancy, normal
pregnant women manifest a different pattern of glucose tolerance from
that of non-pregnant women.

29

Therefore, criteria were needed to define

abnormal glucose tolerance in pregnancy.

In 1964, O'Sullivan and Mahan

28

published a suggested set of criteria based on the results of lOOgm
3 hour OGTTs given to 752 women.

The upper limit of normal was set at

2 standard deviations above the mean for each of the four whole venous
blood glucose levels obtained during the test.

The levels suggested

were: fasting, 90 mg/dl; 1 hour, 165 mg/dl; 2 hour, 145 mg/dl; and
3 hour, 125 mg/dl.

If any two of these limits were reached or exceeded,

the GTT was considered positive.
positive GTTs were followed.

In this study, 255 women who had

Within 8 years, 22.6% of these women were

overt diabetics in the non-pregnant state, and by 16 years 60% of them

■

were diabetic.

These long-term follow-up results have helped validate

the proposed criteria, which are now widely accepted as standards.
Women who demonstrate a positive OGTT are identified as gestational
diabetics.

Controversy exists over the manner in which their diabetes

should be managed.

Some authorities advocate their placement in high-

risk pregnancy clinics, administration of dietary therapy and/or insulin
therapy, measurement of urinary estriols, non-stressed antepartum
monitoring, oxytocin challenge tests, lecithin to sphingomyelin ratio
(L:S), early delivery, and close observations of the neonate in the
first few hours of life with early feeding.13,30-36
these measures unnecessary.

f-jn(j some 0f

However, most authorities agree that women

with positive GTT results should not be treated as routine gravidas.
Women that have positive screening test results and negative
GTT results are generally considered normal gravidas and treated as such
However, on at least one occasion, these women have demonstrated possibl
evidence of abnormal or borderline glucose metabolism (a blood glucose
level of 130 mg/dl or greater during the screening test); they may
have as many as 1 abnormal value and 3 borderline ones among the GTT
results.

It may be suspected that these women do not have fully normal

carbohydrate metabolism, and that they may be at an early stage of the
prediabetes-diabetes continuum,therefore exhibiting some abnormality in
their carbohydrate metabolism, but not sufficient deviation from the
normal to be considered gestational diabetics.

If the above hypothesis

is true, then the question is raised as to whether these women's
pregnancies and their outcome are complicated by factors similar to

gestational diabetics', though may be in a milder form or at a lower
frequency.

Consequently, should these women's pregnancies and newborns

be monitored more closely than those of the routine gravidas?
study addresses this concern.

This

8
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MATERIALS AND METHODS

In a private practice setting, at Yale-New Haven Medical Center,
436 women were screened for gestational diabetes between September 1, 1975,
and May 31, 1980.

From this group, women who fulfilled the following

criteria were included in this study:
1.

A negative screening test, or a positive one followed by a
negative GTT.

2.

Age >_

25 years for at least the 3rd trimester of pregnancy

(for uniformity of the sample; this age group is reported
to have a higher risk of perinatal mortality).
3.

37

Delivery at Yale-New Haven Medical Center (for completeness
of records).

4.

Delivery of a singleton (to eliminate factors that might
confound the results, such as the increased morbidity
associated with multiple births).

Using these criteria, the study sample was composed of 328 women, 77
(23%) of whom had positive screening test results and negative OGTTs,
and, 251 (67%) of whom had negative screening tests, and did not undergo
a GTT.

These two groups were compared.

Screening and OGTT Criteria: In September of 1975, the use of the 50gm
glucose 1 hour screening test described by O'Sullivan et al in 1973,
was adopted at Yale-New Haven Medical Center.

24

Since O'Sullivan et al

had reported that, among women over 25 years of age, there is an increased
risk of perinatal mortality associated with gestational diabetes,

37

-

it was decided to screen all women over that age.

As for women under

25 years, only those that had any of the historical criteria mentioned
in the previous section were to be screened.
At Yale-New Haven Medical Center, a 1 hour glucose level of 130
mg/dl or above is considered a positive screening test and an OGTT is
strongly suggested to the patient.

The level of 130 mg/dl was that

suggested by O'Sullivan et al in 1973, using the Somogyi-Nelson method
and for whole venous blood.

At Yale-New Haven Medical Center, where

the glucose oxidase method is used to report serum glucose measurements,
the equivalent of the 130 mg/dl value suggested by O'Sullivan et al
would be 143 mg/dl.
Amankwahetal (1977)

However, reports by Carpenter and Couston (1981)
39

38

and

suggested that using the adjusted level for plasma

glucose (143 mg/dl) may lead to under diagnosis of gestational diabetes.
Thus, a 130 mg/dl threshold is used.
As for the OGTT results criteria, those described by O'Sullivan
and Mahan

28

in 1964 are used at Yale-New Haven Medical Center. However,

these values are adjusted for the above mentioned factors; therefore,
instead of using 90 mg/dl for the fasting blood, 165 mg/dl for the 1
hour level, 145 mg/dl for the 2 hour level, and 125 mg/dl for the 3 hour
level, 95 mg/dl, 180 mg/dl, 160 mg/dl, and 135 mg/dl are used, respectively.
Management:

Since none of the women in this study had a positive

GTT, they were followed in the routine manner for normal gravidas - unless
a complication developed.

Therefore, they were seen monthly over the

first 30 weeks of pregnancy, biweekly between the 30th and the 36th
weeks, and weekly after the 36th week.

10
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Records of the obstetrical care delivered to the women and the neonatal
hospital stay of their offspring were reviewed to obtain the data
for this study.

Among the data collected were the following variables:

Obesity: Using United States National Health Survey tables for
height and weight,

40

the subjects were divided into subgroups according

to their weight percentile.

Women over the 75th percentile for weight

were considered obese.
Beginning Pregnancy Weight: During the first obstetrical visit
at Yale-New Haven Medical Center women are asked about their pre-pregnancy
weight and it is recorded.
Mid-Pregnancy Weight:

This measurement is needed to calculate

the weight percentile of the infant (as described below).
obtained at the date nearest to 20 weeks was used.

The weight

In the case of late

registrants, whose first recorded weight was at 24 weeks of gestation
or later, a mid-pregnancy weight was approximated by assuming an
average weight gain of one pound per week during that stage of pregnancy.
End Pregnancy Weight:
was used.

The last weight recorded prior to delivery

If the last weight was recorded more than 14 days prior to

delivery, no end pregnancy weight was included in the collected data
for that patient.
Systolic and Diastolic Blood Pressure Ranges:

The maximal and

minimal systolic and diastolic blood pressures recorded during the
pregnancy were used to calculate the systolic and diastolic ranges.
If the highest systolic blood pressure reading was recorded on a different

-
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date from that on which the highest diastolic blood pressure reading
was noted, the set with the highest mean arterial blood pressure was
used for this study.

However, if on the two occasions, the mean

arterial blood pressure was also the same, the set with the higher
diastolic reading was chosen.

Similar criteria were used to collect

minimum blood pressure data.
Gestational Length:

By approximating to the nearest week,

the gestational length was determined using dates - and ultrasound,
where applicable.
Mode of Delivery:

The information recorded on the "birth sheet,"

a form filled in by the obstetrical nursing staff immediately after
birth, was used.
Newborn Special Care Unit (NBSCU):

Since the study sample did not

include women with positive GTT results, pediatricians were not routinely
called to the delivery room, and neonates were not routinely admitted
to the NBSCU for observations.

However, due to cesarean deliveries or

complications, such measures were required for some infants.
.
4i
Weight Percentile: Using Tanner and Thompson graphs (1970),
birth weights were adjusted for sex, mother's height, mother's mid¬
pregnancy weight, length of gestation, and parity.

In cases where the

mother's mid-pregnancy weight exceeded 80 kilograms, the total birth
weight adjustment was 0.500 kilograms.
Congenital Anomalies and Neonatal Complications:

Only those

congenital anomalies and neonatal complications noted during the neonatal

I

-12-

hospital stay were included in the data collected for the study.
Hyperbilirubinemia:

Total bilirubin of 15 mg/dl or greater was

used as the criterion for the presence of hyperbilirubinemia.
Respiratory Difficulties:

All respiratory difficulties that

necessitated an admission to the NBSCU for monitoring and/or therapy
were included.

13

-

RESULTS

Age:

Table 1 illustrates the age distribution of the subjects included

in this study.

Thirty-two of 77 (41.6%) of the women in the positive screen

group and 89 of 251 (35.4%) of the women in the negative screen group
were over 30 years old.

This difference was not statistically significant.

There was a significantly (p <0.05) greater percentage of women over
the age of 35 years in the positive screen group (11.7%) than in the
negative screen group (6.4%).
Table 1, Age Distribution
Pos. Screen
Age

N = 77

N = 251

(No.)

(%)

(No.)

25-30

45

58.4

162

64.5

31-35

23

29.9

73

29.1

36-40

8

10.4

14

5.6

41-44

1

1.3

2

0.8

Mean Age

Race:

Neg. Screen

30.5 years

(%)

29.7 years

Table 2 describes the racial distribution of the women in the

two groups.

No significant differences were evident between them.

Both groups included a high percentage of Caucasians (92.2% and 94.8%
of the positive and negative screening group, respectively).

-
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Table 2, Racial Distribution

Pos. Screen
N = 77

Race

(No.)

{%)

Neg. Screen
N = 251

(No.)

(%)

71

92.2

238

94.8

B1 ack

4

5.2

10

4.0

Oriental

2

2.6

3

1.2

Caucasian

Obesity:

Table 3 depicts the distribution of the women in the study sample
A significantly (p < 0.02) higher

according to their pre-pregnancy weight.

percentage of the women in the positive screen group (15.1%) than in the
negative screen group (7.8%) were obese (at or above the 75th percentile
for weight) prior to the pregnancy reviewed.
Table 3, Maternal Weight Percentile

Pos. Screen
Percentile Range

N = 66*

Neg. Screen
N =219*

(No.)

(%)

(No.)

(%)

Less than 25

27

40.9

116

53.0

25-49

21

31 .8

60

27.4

50-74

8

12.1

26

11.9

10

15.1

17

7.8

Equal to or greater than 75

*The records of 11 women with positive screens and 32 women with negative
screens did not include all the information needed to calculate weight percentiles.

15-
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Obstetrical History:

Table 4 describes the data collected about the

obstetrical histories of the women in the study sample.

No significant

difference is evident between the two groups with respect to parity.
46.7% of the women in the positive screen group and 50.1% of the negative
screen group were nulliparous.
As for positive obstetrical history for spontaneous abortion(s),
as illustrated in table 4, a considerable number of the women that had
positive screens (22/77, 28.6%) had had 1 or more spontaneous abortion
prior to the pregnancy reviewed.

However, when this group was compared

to the negative screen groups, (55/251, 21.9%), the difference was not
significant.
Table 4, Obstetrical History
Pos. Screen
History

N = 77

Neg. Screen
N = 251

(No.)

(%)

(No.)

36

46.7

126

50.1

0

55

71.4

196

78.1

1

13

16.9

38

15.1

2

6

7.8

13

5.2

3

2

2.6

3

1.2

4

1

1.3

1

0.4

0

71

92.2

241

96.0

1

4

5.2

10

4.0

2

2

2.6

0

0.0

Nul1iparous

(%)

Hx of Sp. Ab.

Hx of Stillbirth

16-
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In table 4, the distribution of women in the two groups according
to the history of any prior stil1 birth(s), is depicted.

Among the women

with positive screens, there was a statistically significant (p <0.05)
increased frequency of positive history for stillbirths (7.8%) when compared
to the histories in the negative screen group (4.0%).
Complications of pregnancy:
gain of the two groups.

Table 5 illustrates the patterns of weight

The percentage of women that gained more than 30 lbs

was very similar for the two groups (53.8% of the positive screen group and
52.9% of the negative screen group).
Table 5, Weight Change During Pregnancy

Pos. Screen

*

(No. )

N

il

N = 65*

C\J
C\J

Weight gain
(lbs)

Neg. Screen

(%)

(No. )

(%)

7

10.8

27

12.2

20-29

23

35.4

77

34.8

30-29

19

29.2

82

37.1

40-49

11

16.9

29

13.1

50-59

3

4.6

6

2.7

60 or more

2

3.1

0

0.0

Less than 20

Mean

32.6 lbs

30.3 lbs

*The records of 12 women in the positive screen group and 30 women in the
negative screen group did not include a value for the total amount of weight gain.
Toxemia is a recognized complication associated with gestational
diabetes.

42

Therefore differences in blood pressure ranges for the two

17-
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groups were calculated and compared.
eclampsia were used.

43

Diagnostic criteria for pre-

Table 6 illustrates systolic and diastolic

blood pressure ranges during pregnancy.

In the positive screen group

16/75 (21.3%) had systolic blood pressure range equal to or greater
than 30 mm Hg, while 60/251 (23.9%) of the negative screen group showed
such a range.

No statistically significant difference exists.

As for

diastolic blood pressure measurements, the two groups showed no significant
difference with 34/75 (45.3%) of the positive screen group showing a
range equal to or greater than 15 mm Hg, while 99/251 (39.4%) of the
negative screen group demonstrated similar range.
Table 6, Blood Pressure Ranges
Pos. Screen
Blood Pressure Range
(mm Hg)

Neg. Screen

N = 75*
(No.)

N = 251

(%)

(No.)

(%)

Systolic BP Range
Less than 30

59

78.7

191

76.1

30 or more

16

21.3

60

23.9

Mean

19.9

21.3

Diastolic BP Range
Less than 15

41

54.7

152

60.6

15 or more

34

45.3

99

39.4

Mean

14.4 mm Hg

*2 women did not have complete blood pressure records.

13.4 mm Hg

-ia-

Gestational Length and Mode of Delivery: Diabetics are known
44
to have an increased incidence of premature deliveries.
However, when
comparing the positive screen, negative GTT group to the negative screen
group no significant difference was noted in the incidence of preterm
(< 37 weeks) deliveries.

Nine of 77 (11.7%) of the positive screen group

and 28/251 (11.2%) of the negative screen group delivered within that period.
Table 7 illustrates the distribution of gestational length for the two groups.
Table 7, Gestational Length
Pos. :Screen
Length of Gestation
(wks.)

N ^= 77
(No.)

(%)

30

Neg. Screen
N = 251
(No.)

(%)

1

0.4

1

0.4

33

1

0.4

34
35

1
6

0.4

31
32

1

1.3

1

1.3
3.9
5.2

7

2.8

37

3
4

n

4.4

38

13

16.9

21

8.4

39
40

21

53

21.1

13

27.3
16.9

85

33.9

41

13

16.9

45

17.9

42

7

9.1

18

7.2

43

1

1.3

1

0.4

36

Mean

39.28 (39 2/7 wks)

2.4

39.47 (39 3/7 wks)

Table 8 delineates the frequency of the different modes of del ivery among
the two groups.

The modes were grouped according to the situation that may

-19-

require a certain method.

When comparing the positive screen group of

women to the negative screen group with respect to mode of delivery, no
significant difference was noted in the group of modes that may be
necessitated by a macrosomic baby - namely, mid forceps, vacuum, and
cesarean section for failure to progress.

Eleven of 77 (14.3%) of the

positive screen group and 40/251 (15.9%) of the negative screen group was
delivered by such a method.

No other statistically significant variation

was evident between the two groups of women with respect to mode of delivery.
Table 8, Mode of Delivery
Pos. Screen
Mode of Delivery

Neg. Screen
N = 251

N = 77
(No.)

(%)

(No.)

(%)

Spon. Vag. Del.,
Low Forceps Del.

52

67.5

185

73.7

Mid Forceps Del.,
Vacuum, FTP C-section

11

14.3

40

15.9

Fetal Distress C-section

2

2.6

3

1 .2

Abnormal lie

6

7.8

7

2.8

Repeat C-section,
C-section for Herpes

6

7.8

16

6.4

Neonatal Distress:

Table 9 depicts the percentage of newborns that had

an APGAR score of less than 7 at 1 or 5 minutes of life.

Of the positive

screen group 9.1% and 3.9% had APGAR scores of less than 7 at 1 and 5 minutes,
respectively.

Of the negative screen group 8.0% and 2.4% had APGAR scores

of less than 7 at 1 and 5 minutes, respectively.

There are no significant

-20-

differences in the distribution of APGAR scores or their means when the
positive and negative screen groups are compared.
Table 9, APGAR Scores
Pos. Screen
APGAR Scores

N = 77
(No.)

(%)

Neg. Screen
N = 251
(No.)

(%)

APGAR @ 1 min less than 7

7

9.1

20

8.0

APGAR @ 1 min equal to or
greater than 7

70

90.9

231

92.0

Mean APGAR @1 min

8.35

APGAR @ 5 min less than 7

3

3.9

6

2.4

APGAR @ 5 min equal to or
greater than 7

74

96.1

245

97.6

Mean APGAR @ 5 min

8.29

8.78

8.88

Table 10 illustrates the distribution of newborns with respect to the
type of facility to which they were transferred after their birth.

Some

were sent to a well-baby nursery (no NBSCU admission), others were admitted
to the NBSCU for a 6 hour observation and monitoring period, and the rest
were admitted to the NBSCU for therapy and close monitoring.

Although a

higher percentage of the positive screen group newborns (18.2%) than the
negative screen group infants (13.2%) required NBSCU admissions, the
difference was not statistically significant.

.
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Table 10, Admissions to NBSCU
Pos. Screen
Type of Admission to NBSCU

N = 77

Neg. Screen
N = 251

(No.)

(*)

(No.)

No admission

53

68.8

179

71.3

6 hr. observation

10

13.0

39

15.5

Admission

14

18.2

33

13.2

(%)

Hyperbilirubinemia is recognized as a neonatal complication associated
with diabetes in pregnancy.

45

Table 11 depicts the incidence of hyper¬

bilirubinemia, of other neonatal complications, and of congenital anomalies.
Although there was a higher incidence of hyperbi1irubinemia (total bilirubin
equal to or greater than 15) among the infants of the positive screen group
(13.0%) when compared to the neonates of the other group (8.0%), the
difference did not reach statistical significance.
As for other neonatal complications, as depicted in table 11, the
incidence of respiratory difficulties was significantly (p <0.02) greater
among the infants of the positive screen group (8/77, 10.4%) in
to those of the negative screen group (5/251, 2.0%).

comparison

Hypoglycemia (abnormally

low Dextrostix^ readings) was noted in 1/77 (1.3%) of the positive screen
group newborns and in 2/251 (0.8%) of the negative screen infants.

It

should be noted that since none of the women in this study had abnormal
0GTT results, blood glucose measurements of any kind were not performed
unless the infant's symptoms suggested that he/she might be suffering from
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hypoglycemia.

Six other infants of the negative screen group had

neonatal complications of miscellaneous nature (e.g. sepsis, irregular heart
beat, etc.) that are unlikely to be related to the mother's carbohydrate
metabolism.
There is an increased incidence of congenital anomalies among the
infants of diabetic mothers.

46-48

However, in comparing the positive

screen and the negative screen groups studied here, no significant difference
in the incidence of congenital anomalies was apparent.

Among the positive

screen group neonates, 3/77 (3.9%) had congenital anomalies.
were: a

The anomalies

preauricular skin tag, bilateral congenital hydrocele of the scrotum,

and blisters of unknown etiology on the hands of the third baby (healed
spontaneously).

Among the negative screen group infants, 10/251

(4.0%)

had congenital anomalies and they ranged from a hip click to a question of
ventricular septal defect.
Table 11, Neonatal Complications and Congenital Anomalies

Pos. Screen
Complications & Anomalies

N = 77
(No.)

Hyperbi1irubinemia

(%)

Neg. Screen
N = 251
(No.)

(%)

10

13.0

20

8.0

8

10.4

5

2.0

1

1.3

2

0.8

Sepsis

0

0.0

4

1 .6

Other Complications

0

0.0

2

0.8

Congenital Anomalies

3

3.9

10

4.0

Respiratory Difficulties
Dextrostix

@

reading _<

45
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Birth Weight and Neonatal Size:
of birth weights.

Table 12 delineates the distribution

Among the women with positive screens there was a

significantly (p <0.02) higher incidence of neonates weighing 4000
grams or more.

Eleven of 77 (14.3%) of the neonates of this group weighed

4000 gms or more while only 19/251

(7.6%) of the negative screen neonates

were in the same weight range.
Table 12, Birth Weight

Pos. Screen
Birth Weight
(grams)

N = 251

N = 77
(No.)

Less than 2000

Neg. Screen

(%)

(No.)

(%)

1

1.3

3

1.2

2000-2999

12

15.6

57

22.7

3000-3999

53

68.8

172

68.5

4000 or more

11

14.3

19

7.6

Mean

3403. 4 grams

3285 .7 grams

Despite this difference in the incidence of newborns weighing 4000
grams or more, no significant difference in the numbers of infants above
the 75th percentile was seen between the two groups when the birth weights
were adjusted for sex, mother's height and mid-pregnancy weight, gestational
age, and parity (Tanner and Thompson ^ graphs used).

Table 13

depicts the distribution of newborns according to weight percentile.
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Table 13, Birth Weight Percentile Distribution

Pos. Screen
Percentile Range

Neg. Screen

N = 76*

N = 250*

(%)

(No.)

(No.)

(%)

(%)

Less than 25th

21

27.6

85

34.0

25-49

25

32.9

81

32.4

50-74

17

22.4

49

19.6

Greater than 74th

13

17.1

35

14.0

*2 subjects with positive screens and 1 with negative screen did not
have all information needed for the calculation of these percentile values.
Another measure of macrosomia is that of body fat.
index was used as such a measure.

The ponderal

The ponderal index is equal to the

ratio of the weight in pounds to the value of the length in centimeters
cubed.
Merritt

The index was calculated for each infant.
49

was used to obtain the percentile ranges.

A table by Miller and
Table 14 depicts

the distribution of the values obtained and the percentile range for
each category.
the two groups.
both groups.

No significant differences were evident when comparing
The mean ponderal index was in the 52nd percentile for
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Table 14, Ponderal

Index

Pos. Screen

Neg. Screen

N = 65*

Ponderal Index
(gm/cnr)
and (percentile)

N = 219*

(%)

(No.)

20

30.8

71

32.4

2.41-2.53 (25-49%)

11

16.9

39

17.8

2.54-2.67 (50-75%)

11

16.9

41

18.7

Greater than 2.67 (75%)

23

35.4

68

31.1

(No. )

Less than 2.41

(25%)

Mean

2. 558 gm cm

_3

(*)

2.554 gm cm ^

*12 newborns of the positive screen group and 32 of the negative screen
group did not have lengths recorded in their charts.
Results of QGTT vs. Birth Weight and Weight Percentile: Table 15 depicts
the distribution of the subjects that had positive screening test results
according to the presence of an abnormal glucose level, and the number
of borderline values (within 10 mg/dl of the upper limit for normal),
present in the OGTT results.

Also in table 15, an attempt is made to

investigate the presence of a correlation between the results of the
OGTT and the outcome of the pregnancy.

In each category of abnormal or

borderline values, the number of newborns weighing 4000 grams or more
and/or being in the 75th percentile or above is depicted.

Of interest,

none of the 3 infants whose mothers had 1 abnormal value and 2 borderline
ones was large by the criteria used, while 20.6% of the women that had no
abnormal or borderline values in the OGTT results delivered large babies
by either or both of the criteria used.

No correlation between the OGTT

results and the weight of the baby was evident.
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Table 15, OGTT Results vs. Birth Weight and Weight Percentile

OGTT Results
(points)

No. of newborns
with weight >_ 4000 gm
or percentile > 75

Category
Total
N=71 *

Percent of
large babies
in category

1 Abnl. +2 Borderline

0

3

0.0

1 Abnl. +1 Borderline

1

4

25.0

1 Abnl.

2

9

22.2

3 Borderline

0

3

0.0

2 Borderline

1

4

25.0

1 Borderline

3

14

21.4

0 Abnl. 0 Borderline

7

34

20.6

*The records of 6 subjects did not include all the information necessary
for inclusion in this table.
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DISCUSSION

In this retrospective study, a group of pregnant women having
positive screens and negative OGTTs was compared with a group of women
having negative screens.

Since the women in both groups had been con¬

sidered routine gravidas, it was assumed that there had been no bias
in the type of health care delivered to them.

Differences noted between

the two groups were considered statistically significant if the calculated
p was less than 0.05.

This meant that the likelihood for a significant

difference to appear due to chance alone was 1 in 20.

Therefore, for

every 20 variables studies, 1 statistically significant difference
might appear randomly.
Given that 37 variables were considered in this study, it is
conceivable that the two groups might differ with respect to two variables
on the basis of chance alone.

However, they differed with respect to 5

variables, approximately twice the predicted number.

In addition, the

difference noted depicted variations in the direction that would be
expected if the hypothesis proposed was valid.

Were chance alone the

cause of the noted differences, it would have been unlikely for all the
differences to support the hypothesis.

The number of variables with

respect to which differences were noted, and the general trend of these
differences, favor the notion that the two groups intrinsically differ
in certain respects.

Some of the variables examined are discussed below.

Age: In 1968, Grimaldi reported that the prevalence of gestational
diabetes is significantly greater among women over the age of 30 years.

50

Other investigators have reported that the mean age of gestational diabetics
tends to be higher than that of nondiabetics.

51 -52

In this study, a similar

\
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tendency exists with 11.7% of the women in the positive screen group
being over the age of 35 years as compared to 6.4% of the negative
screen group.

However, the mean age of the women in the two groups was

not significantly different.

It is tempting to consider these results

as supportive of the proposed hypothesis.
Obesity: Gestational diabetes has been related to obesity.

51

If

subjects with a positive screening test and a negative GTT are part
of the prediabetes continuum, obesity might be more common in this group
of women compared to those with a negative screening test.

In the present

study, such a relationship did exist, with 15.1% of the positive screen group
being above the 75th percentile for pre-pregnancy weight as compared to
7.8% of the negative screen group.
Obstetrical History: In 1966, Dandrow and O'Sullivan reported a
significant difference in parity between gestational diabetics and non¬
diabetics (mean parity among gestational diabetics was 4.2 while that of
the nondiabetics was 2.2).
observations.

52

51

Other reports have pointed to similar

Therefore, women in the two groups of this study were

compared to investigate the presence of an association between parity
and the incidence of positive screens and negative OGTT.

With the two

groups having similar numbers of multiparous and nulliparous women in
them, no such association was evident.
The incidence of spontaneous abortions among diabetic women is
thought to be the same as that of the general population.

53

However,

the former group demonstrates an increased incidence of intrauterine
deaths.

51 54
’

The two groups studied here demonstrated no significant

difference with respect to the incidence of history for spontaneous abortion(s).
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However, 7.8% of the positive screen group versus 4.0% of the negative screen
group had a positive history of stillbirth(s) - a significant difference.
These results are consistent with those expected if the hypothesis proposed
in this study were valid.
Complications of pregnancy: It may be suspected that pregnant
women who gain an excessive amount of weight ( .>30 lbs.) are more likely
to have a positive screening test than women that undergo a smaller amount
of weight gain.

The results of this study did not confirm this suspicion.

53.8% of the positive screen group and 52.9% of the negative screen group gained
30 or more pounds.
Preeclampsia is reported to occur at higher rates among diabetics
than nondiabetics.

42

In this study, blood pressure ranges were used as

indicators of possible preeclampsia.

The two groups were compared with

respect to the range of the systolic blood pressure readings and to that
of the diastolic blood pressure readings.

In calculating the range for

systolic blood pressure for a specific subject, the maximum and the minimum
blood pressure measurements were compared.

These two values might have

been recorded at any time during the pregnancy, and one or both of them
might have been atypically high or low for the patient's usual blood pressure
readings.

The same was true for diastolic blood pressure range calculations.

Adapting accepted criteria for the diagnosis of preeclampsia to the present
study,

43

a value

30 mm Hg for systolic blood pressure range and a value

^ 15 mm Hg for diastolic blood pressure range were used as criteria for
comparison of the two groups.

No significant difference was evident.

The frequencies of women meeting these criteria may seem high for both

30

-

the negative and the positive screen group (23.3% of the total study
sample met the criteria for large systolic blood pressure range and
40.8% met the criterion for large diastolic blood pressure range).
However, it should be noted that these frequencies do not indicate the
true incidence of preeclampsia.

Considering the method in which these

frequencies were obtained, it is evident that their significance is not
in their absolute values, but rather in their being a measure of comparison
for the two groups.
Gestational length and neonatal complications: Prematurity and
its associated complications are well known causes of increased neonatal
morbidity and mortality among the infants of diabetic mothers. 55-56
The two groups in this study were compared with respect to gestational
length.

No correlation between positive screens (that were followed by

negative OGTTs) and prematurity was evident.

11.7% and 11.2% of the

positive screen group and of the negative screen group, respectively,
gave birth during or before the 37th week of gestation.

In addition,

there was no significant difference between the two groups in the number
of neonates with APGAR scores of less than 7 at 1 or 5 minutes.
Hyperbi1irubinemia occurs with greater frequency among the newborns
of diabetics than among the newborns of nondiabetics.56-58

The mechanism

57
56
for the increased incidence is not well understood.
Prematurity,
59
the use of oxytocin to induce vaginal delivery,
increased extramedullary
fin
hematopoeisis and increased hematocrit in macrosomic babies,
are some
of the causal factors that have been implicated.

Between the positive

screen group and the negative screen group no statistically significant

-

C

-3.1 -

difference was noted with respect to the incidence of hyperbilirubinemia.
Respiratory distress syndrome (RDS) of the neonate is another
complication associated with diabetic pregnancies.

12

However, with

the use of the L:S ratio before delivery, and other factors (possibly
including improved maternal diabetic control), the incidence of neonatal
RDS in the infants of diabetics is decreasing.

57

The two groups in this

study were compared with respect to respiratory difficulties that necessitated
admissions to the NBSCU.

10.4% of the neonates of the positive screen

group had such difficulties while only 2.0% of the negative screen group
did.

This is a statistically significant difference (p

<0.02).

However,

when the two groups were compared with respect to the incidence of the neonatal
diagnosis of RDS, no significant difference was apparent (2/77 neonates in
the positive screen group and 2/251 of the neonates in the negative screen group).
As for neonatal hypoglycemia, a well recognized neonatal complication of
diabetic pregnanciesthere was no significant difference in its
incidence between two groups compared in this study.
Congenital Anomalies: Most authorities agree that congenital anomalies
occur with increasing incidence in the newborns of diabetic mothers
when compared to newborns of nondiabetics.

4 46-48
5

As antenatal and

perinatal care improves, congenital anomalies are causing an increasing
proportion of the neonatal mortality rate among infants of diabetic mothers.
In this study, no significant difference was noted in the incidence of
congenital anomalies, when the neonates of the positive screen group were
compared to those of the negative screen group.

Three of 77 newborns in

the positive screen group had minor anomalies (a preauricular skin tag.

62
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a bilateral congenital hydrocele of the scrotum, and blisters of
unknown etiology on the hands).

This low rate of congenital anomalies

is not surprising in view of the fact that gestational diabetics have a
lower incidence of congenital anomalies than overt diabetics.

Women

with positive screening tests and negative OGTTs would be expected to
have even lower rates than gestational diabetics.
Macrosomia: Macrosomia (defined by most investigators as a birth
weight equal to or greater than a specific weight, usually between 3500
and 4500 grams) is a common complication associated with diabetic
pregnancies.

4 36
’

Godel et al reported that infants born to diabetic mothers

between the 35th and 39th week of gestation, weigh about 500-600 grams more
than infants of nondiabetic mothers of similar gestational age.

63

Among

macrosomic infants, traumatic morbidity during vaginal delivery resulting
in shoulder dystocia, Erb's palsy, and broken bones is increased.

64

Therefore, it is important to identify women who are likely to give birth
to macrosomic infants.

In this study, the mean birth weight of the

neonates in the positive screen group was not significantly different from
that of the neonates of the negative screen group.

However, the former

group had a significantly higher percentage of babies (14.3%) weighing 4000
grams or more as compared with the latter group (7.6%).

The disparity

in the incidence of macrosomic infants ( >_ 4000 grams) between the two
groups may be secondary to factors other than carbohydrate metabolism
(e.g. gender, maternal obesity).
birth weights than girls.

65

Boys tend to have somewhat larger

Since there was a higher percentage of boys

among the neonates of the positive screen group (62.3%), than among those
of the negative screen group (50.6%), a higher incidence of macrosomic
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babies would be expected among the positive screen group than among the
negative screen group.

In addition, obese women are known to deliver

larger babies than normal weight women of the same height.

Therefore,

another factor is the fact that there was a higher incidence of obesity
among the women in the positive screen group than the negative screen one.
Both maternal obesity and neonatal gender can be corrected for
in calculating birth weight percentiles.

Tanner and Thompson

41

graphs

were used and percentiles were calculated after adjusting the birth weights
for maternal mid-pregnancy weight, height, parity, neonatal sex, and
gestational age.

There was no difference between the two groups in the

incidence of babies in the 75th percentile or above it.

These findings

suggest that women in the positive screen group are more likely to deliver
macrosomic babies due to maternal obesity or other reasons not necessarily
directly related to carbohydrate metabolism.
Macrosomic babies of diabetic mothers have high fat content in their
bodies.

66

The ponderal index is

often used in assessing macrosomia,

because it is an indicator of body fat content.
and a table by Miller and Merritt

49

percentile value for each neonate.

49

The index was calculated

was used to estimate the ponderal index
There were similar numbers of neonates

above the 75th percentile in the two groups.

These findings suggest that

the infants of women who have positive screens and negative GTTs are not
more likely to have high fat content than the infants of women that have
negative screens.
Mode of delivery: If women with positive screens and negative OGTTs
have an increased incidence of delivering macrosomic infants, then an
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increase in the frequency of operative delivery might be expected (i.e.
mid forceps deliveries, vacuum extractions, and cesarean deliveries for
failure to progress).

With respect to the rate of use of these methods of

delivery, no significant difference was noted between the positive screen
group (14.3%) and the negative screen group (15.9%).
GTT results and pregnancy outcome: If some of the women that have
positive screens and negative OGTTs are at risk for a higher incidence
of perinatal morbidity and mortality, it would be helpful if they could be
identified by using their OGTT results.

Table 15 demonstrates no correlation

between the results of the OGTT (the presence of one abnormal value and/or
borderline level(s)) and the weight of the newborn.
In summary, in comparing a group of women with positive screening
tests and negative OGTTs to a group of women with negative screening
tests, no significant differences were noted with respect to racial dis¬
tribution, parity, history of spontaneous abortion(s), weight gain during
pregnancy, blood pressure range, gestational length, modes of delivery,
APGAR scores, NBSCU admissions, incidence of hyperbilirubinemia, incidence
of RDS, incidence of neonatal hypoglycemia, congenital anomalies, weight,
percentile, or ponderal index.

However, statistically significant

differences were evident with respect to the presence of women over the
age of 35 years, obesity, history of stillbirth(s), incidence of neonatal
respiratory difficulties, and of birth weight >_ 4000 grams.
Considering that the two groups demonstrated significant differences
with respect to 5 variables, 2 of which may have been due to random change
(as discussed previously), the findings of this study do not prove or
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disprove the hypothesis proposed (that the women with positive screens
are at an earlier stage of the prediabetes-diabetes continuum than
gestational diabetics).

The few differences found, if not due to chance,

are not significant enough for one to consider women with positive screens
and negative OGTTs abnormal.

Actually, the results of this study offer

the practitioner added support in reassuring women that a positive screening
test followed by a negative OGTT is not associated with significant increase
in the morbidity of the pregnancy.
It may be argued that the positive findings of this study could be
viewed as indicators that the carbohydrate metabolism of women with positive
screens and negative OGTTs is different from that of normal women, and
therefore, these women may be at an early stage of prediabetes.

Whether

this argument is valid can be determined through long term follow-up
of such women for the possible development of diabetes during subsequent
pregnancies.
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APPENDIX
Data Sheet

MO's Unit #:_Baby's Unit #:

Code #:_

1st Born: Yes_No_Total Bili.(Max):__

Del . Date:_

Other Information:

Code

Group

(J (_) (J
1

2

Still B

(J
14

Hr 2 GTT

3

Mo's Age

(J

(J (J

4

5

(J (J (J

6

7

8

to Screen

Hr 1 Screen

(J (J

(_)(_)(_)

(_)(_)(_)

17 18 19

20 21 22

15

16

Hr 3 GTT

Del Sex

NBSCU

( )( )
51 52

( )
53

( )
67

Race

ScreenWk

GesLng

( )( )( )()()()( )( )
31 32 33 34 35 36 37 38

CongAnom

Height

APGAR1
( )
54

Beg Preg Wt

9

Para

SpAb

ThAb

?Ab

(J

(J

(J

o

10

GTT Wk

11

12

FBS GTT

13

Hr 1 GTT

(_)(_) (J(_)(_) (J(JL)
23 24

25 26 27

Mid Preg Wt

28 29 30

End Preg Wt

( )( )()()( )( )( )( ) ( )( )( )( )
39 40 41 42 43 44 45 46 47 48 49 50

APGAR5

Birth Wt

( )( )
55 56

( )( )( )( )
57 58 59 60

Percent
( )( )
61 62

Length

Lght

( )( )( )
63 64 65

MinS.ys BP

MinDias BP

MaxSys BP

MaxDias BP

()()()
68 69 70

()()()
71 72 73

()()()
74 75 76

( )( )( )
77 78 79

( )
66

BP Read Meth
( )
80
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